March 7, 2022 -- Felix Biotechnology received a strategic investment from the Cystic Fibrosis Foundation as part of a Therapeutics Development Award. The award will bolster Felix's work on creating a novel therapy to manage chronic Pseudomonas aeruginosa lung infections.
The company said that its phage therapies are specially designed to consider and drive advantageous evolutionary outcomes of phage treatment, resulting in a more durable therapy.
The therapy is currently being evaluated in a clinical trial at Yale University. Felix's discovery and engineering technology platforms are built on technology from Yale and Lawrence Berkeley National Laboratory.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
